Adicet Bio announces 1-for-16 reverse stock split effective Dec 30, 2025; reduces shares from ~153.3M to ~9.6M

Adicet Bio, Inc.

Board approved 1-for-16 reverse split within previously authorized 1:5 to 1:30 range; effective 12:01 a.m. ET Dec 30, 2025.
Outstanding shares drop from ~153.3 million to ~9.6 million; authorized shares unchanged at 300 million.
Purpose: regain compliance with Nasdaq minimum bid price requirement for continued listing.
No fractional shares issued; holders receive cash in lieu; proportional adjustments to equity plans and warrants.
CUSIP number changes to 007002207; trading symbol remains ACET.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Adicet Bio, Inc.: Effective as of December 30, 2025, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-16 reverse stock split of its common stock (effective 2025-12-30).

Change: charter amendment
Effective: 2025-12-30

Exact text from the filing

On December 26, 2025, Adicet Bio, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

Browse all governance changes →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-332343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.